Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Georgina S. Daher-Reyes"'
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e477-e482
Background The incidence and risk factors for invasive mold infections (IMI) in acute myeloid leukemia (AML) patients carrying FLT3 mutations have not been addressed. Patients and Methods This retrospective cohort included FLT3-mutated AML patients (
Autor:
Wilson Lam, Caroline J McNamara, Dennis Dong Hwan Kim, TaeHyung Kim, Jonas Mattsson, Zhaolei Zhang, Hassan Sibai, Rajat Kumar, Armin Gerbitz, Steven M. Chan, Karen W.L. Yee, Jose Mario Capo-Chichi, Tracy Murphy, Dawn Maze, Georgina S. Daher-Reyes, Andre C. Schuh, Aaron D. Schimmer, Igor Novitzky-Basso, Arjun Law, Tracy Stockley, Kyuoung Ha Kim, Jeffrey H. Lipton, Zeyad Al-Shaibani, Mark D. Minden, Adam C. Smith, Ivan Pasic, Fotios V. Michelis, Auro Viswabandya, Vikas Gupta
Publikováno v:
Bone Marrow Transplantation. 56:1908-1918
The impact of adverse risk genetic profiles on outcomes in acute myeloid leukemia (AML) patients following allogeneic hematopoietic stem cell transplantation (HCT) has not been fully elucidated. Accordingly, we have profiled somatic mutations at diag
Autor:
Andrea Arruda, Vikas Gupta, Tracy Murphy, Jinfeng Zou, Caroline J McNamara, Anne Tierens, Karen Yee, Mark D. Minden, Hassan Sibai, Mariam Korulla, Suzanne Kamel-Reid, Dawn Maze, Andre C. Schuh, Steven M. Chan, Tracy Stockley, Scott V. Bratman, Georgina S. Daher-Reyes, Aaron D. Schimmer
Publikováno v:
Blood Advances. 3:2307-2311
Key Points DNMT3A R882, TET2, ASXL1, and SRSF2 mutations identified at the time of diagnosis are associated with delayed count recovery. Persistence of preleukemic mutations in remission at high variant allele frequency is associated with delayed cou
Publikováno v:
Expert opinion on investigational drugs. 28(10)
Introduction: The incidence of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) is increasing with the aging population. Prognosis and overall survival (OS) remain poor in elderly patients and in those not eligible for intensive treat
Autor:
Vikas Gupta, Georgina S. Daher-Reyes, Hassan Sibai, Aaron D. Schimmer, Caroline J McNamara, Anne Tierens, Dawn Maze, Mark D. Minden, Muhned Alhumaid, Steven M. Chan, Andre C. Schuh, Karen W.L. Yee, Dennis Dong Hwan Kim, Tracy Murphy, Igor Novitzky-Basso
Publikováno v:
Blood. 136:8-9
BACKGROUND: Multiparameter flow cytometry (MFC) has increasingly been used for measurable residual disease (MRD) assessment in patients with acute myeloid leukemia (AML), while next-generation sequencing (NGS)-based MRD monitoring tool is in clinical
Autor:
Mark D. Minden, Dawn Maze, Caroline J McNamara, Vikas Gupta, Andre C. Schuh, Steven M. Chan, Muhned Alhumaid, Georgina S. Daher-Reyes, Eshetu G. Atenafu, Karen W.L. Yee, Wilson Lam, Tracy Murphy, Arjun Law, Hassan Sibai, Gil Yerushalmi, Aaron D. Schimmer
Publikováno v:
Blood. 134:2609-2609
Introduction: Clinical outcomes of acute myeloid leukemia (AML) in adolescents and young adults (AYA) are rarely reported as an isolated subgroup. Treatments vary little across age groups, and treatment intensity depends upon comorbid conditions and
Autor:
Lynn Savoie, Elena Liew, Lambert Busque, Georgina S. Daher-Reyes, Donna L. Forrest, Robert Delage, Suzanne Kamel-Reid, Mary-Margaret Keating, Pierre Laneuville, Isabelle Bence-Bruckler, Kristjan Paulson, Brian Leber, Dennis Dong Hwan Kim, Jeffrey H. Lipton, Anargyros Xenocostas
Publikováno v:
Blood. 134:1653-1653
Introduction: Tyrosine kinase inhibitor (TKI) therapy can result in the adverse events of prolonged anemia, thrombocytopenia and/or leukopenia via c-kit blockade in hematopoietic stem cells. Previous studies have reported that even low-grade adverse
Autor:
Vikas Gupta, Andre C. Schuh, Caroline J McNamara, Jeffrey H. Lipton, Aaron D. Schimmer, Tracy Stockley, Jose Mario Capo-Chichi, Jonas Mattsson, Rajat Kumar, Arjun Law, Dawn Maze, Zeyad Al-Shaibani, Auro Viswabandya, Mark D. Minden, Karen W.L. Yee, Zhaolei Zhang, Wilson Lam, Dennis Dong Hwan Kim, TaeHyung Kim, Steven M. Chan, Georgina S. Daher-Reyes, Jae-Sook Ahn, Hassan Sibai, Kyoung Ha Kim, Fotios V. Michelis, Tracy Murphy
Publikováno v:
Blood. 134:3317-3317
Introduction: The introduction of next-generation sequencing (NGS) has expedited the discovery of novel genetic lesions in acute myeloid leukemia (AML), thereby allowing better risk stratification with respect to overall survival (OS). We have previo
Autor:
Pierre Laneuville, Kristjan Paulson, Lambert Busque, Donna L. Forrest, Elena Liew, Mary-Margaret Keating, Anargyros Xenocostas, Dennis Dong Hwan Kim, Robert Delage, Suzanne Kamel-Reid, Brian Leber, Jeffrey H. Lipton, Georgina S. Daher-Reyes, Lynn Savoie, Isabelle Bence-Bruckler
Publikováno v:
Blood. 134:2933-2933
Introduction: The Canadian tyrosine kinase inhibitor (TKI) discontinuation trial has reported a 59.1% and 21.5% molecular relapse-free survival (RFS) rate after first attempt of treatment free remission (TFR1) with imatinib (IM) discontinuation and a
Autor:
Rebecca Devlin, Nisha Kanwar, Hubert Tsui, Mark D. Minden, Jie Su, Tracy Stockley, Andre C. Schuh, Auro Viswabandya, Jaime O. Claudio, Karen Yee, Steven M. Chan, Jenny M.-Y. Ho, Nancy Siddiq, Hassan Sibai, Tony Panzarella, Caroline J McNamara, Dawn Maze, Mahadeo A. Sukhai, Andrea Arruda, Suzanne Kamel-Reid, Vikas Gupta, James A. Kennedy, Georgina S. Daher-Reyes, Aaron D. Schimmer
Publikováno v:
Blood advances. 2(20)
There is a paucity of data regarding the impact of mutations on outcomes in accelerated-phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs). Moreover, it is unknown whether mutational status affects survival, as seen in chronic-phase